Version 2 2021-06-01, 15:46Version 2 2021-06-01, 15:46
Version 1 2021-05-24, 21:06Version 1 2021-05-24, 21:06
journal contribution
posted on 2021-06-01, 15:46authored byCarolina
A. Ferreira, Shreya Goel, Emily B. Ehlerding, Zachary T. Rosenkrans, Dawei Jiang, Tuanwei Sun, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Dalong Ni, Weibo Cai
Theranostic
nanoparticles hold the potential to greatly improve
cancer management by providing personalized medicine. Although many
theranostic nanoconstructs have been successful in preclinical studies,
clinical translation is still hampered by their limited targeting
capability and lack of successful therapeutic efficacy. We report
the use of novel ultrasmall porous silica nanoparticles (UPSN) with
enhanced in vivo pharmacokinetics such as high target
tissue accumulation (12% ID/g in the tumor) and evasion from the reticuloendothelial
system (RES) organs. Herein, UPSN is conjugated with the isotopic
pair 90/86Y, enabling both noninvasive imaging as well
as internal radiotherapy. In vivo PET imaging demonstrates
prolonged blood circulation and excellent tumor contrast with 86Y-DOTA-UPSN. Tumor-to-muscle and tumor-to-liver uptake values
were significantly high (12.4 ± 1.7 and 1.5 ± 0.5, respectively),
unprecedented for inorganic nanomaterials. 90Y-DOTA-UPSN
significantly inhibits tumor growth and increases overall survival,
indicating the promise of UPSN for future clinical translation as
a cancer theranostic agent.